Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Susanna Banerjee noted surprising durable responses during early trials of avutometinib combined with defactinib in patients whose disease had already progressed on MEK or BRAF inhibitors. The RAMP-201 trial permitted prior MEK exposure, demonstrating that simultaneous vertical and parallel pathway inhibition bypasses reactivation.

Related Insights

While initial response rates are similar between the Avutometinib/Defactinib doublet and single-agent Trametinib, the doublet provides double the progression-free survival (PFS). Its remarkable duration of response (over 30 months) indicates superior long-term disease control.

The clinical success of re-challenging patients with a different TKI after progression is not just about hitting VEGF harder. TKIs are 'dirty' drugs that also target other kinases like MET and AXL, which are present on immune cells like tumor-associated macrophages (TAMs), providing a distinct immunomodulatory effect.

The new drug avutometinib uses a "RAF-MEK clamp" mechanism, blocking two nodes in the RAS pathway simultaneously (RAF and MEK). This dual-inhibition strategy is more effective than single-node targeting because it preempts the cancer cell's adaptive resistance mechanisms, where the pathway reactivates itself in response to upstream blocking.

Susanna Banerjee reported that the RAMP-201 study achieved a 17% response rate in KRAS wild-type tumors, contrasting with historic standard of care response rates of roughly 7%. This activity demonstrates that vertical RAF-MEK clamping combined with FAK inhibition extends benefit beyond the minority of patients carrying KRAS alterations.

A patient who failed trametinib later responded to the avutametinib/defactinib combination. This suggests that resistance to one MEK inhibitor does not preclude a response to a different agent or combination targeting the same pathway, offering a viable later-line treatment strategy.

By targeting MEK, which is downstream of RAS/RAF in the MAPK pathway, Immuneering's therapy can block a wider range of potential resistance mutations. This preempts the cancer's ability to adapt by mutating upstream proteins, a common failure point for drugs that target RAS directly.

In KRAS-mutant low-grade serous ovarian cancer, blocking RAS-RAF-MEK signaling triggers compensatory FAK pathway upregulation as an escape mechanism. Combining the RAF/MEK clamp avutametnib with FAK inhibitor defactinib abrogates this bypass resistance, demonstrating notable activity that recently secured accelerated FDA approval.

Earlier MEK inhibitors caused severe mucositis and gastrointestinal toxicities without survival benefit due to continuous pathway inhibition. Atibimetinib features a short two- to three-hour half-life that inhibits MEK and ERK phosphorylation without triggering CRAF-driven bypass resistance. Crucially, the transient drug exposure allows normal cells time to reset, substantially improving tolerability compared to prior continuous-dosing regimens.

The Avera trial’s design combined jiridestrant with everolimus to simultaneously target the primary estrogen-driven pathway and a known parallel resistance pathway (mTOR/PI3K/AKT). This created two blockades to prevent cancer cells from finding an escape route, showcasing an elegant trial strategy.

The RAMP-201 trial showed the combination of Avutometinib and Defactinib achieved a 25% response rate even in patients who had progressed on or were intolerant of prior single-agent MEK inhibitors. This establishes the doublet as an effective subsequent line of therapy in a resistant population.